In this issue of ViaConnect, we've pulled together the latest in newborn genomics, cord blood research, and patient-centred updates.
Stem Cell Updates Cord Blood Therapy Shows Promise for Children with Cerebral Palsy
A recent meta-analysis published in Pediatrics, reviewed data from 11 studies to explore the potential of umbilical cord blood (UCB) therapy to support motor function improvement in children with cerebral palsy. The analysis of nearly 500 participants suggested promising trends, particularly among younger children and those receiving higher cell doses. The study adds to ongoing efforts to better understand the role of UCB in neurodevelopmental research.
In honor of Celiac Awareness Month, families who enroll in Cord Blood or Cord Blood + Tissue banking with ViaCord between May 12–25 will receive Newborn Digestive Health (a $250 value) at no extra cost. This add-on screens for genetic risk of celiac disease using a sample of the baby’s cord blood—providing early insights that may support future care.
Genomics in Practice WGS Identifies Conditions Missed by Traditional Tests
Early results from major studies like the Guardian study in New York and BabyDetect project in Belgium are showing how genome sequencing can catch life-altering conditions missed by traditional newborn screening. At ViaCord, Whole Genome Sequencing is available for newborns (using preserved cord blood) as well as adults, aligning with the advancements highlighted in these studies. While challenges around cost, data, and clinical follow-up remain, the technology is proving effective in identifying treatable conditions sooner—opening the door to earlier intervention and better outcomes.
The CORD-SaFe study found that collecting and reinfusing autologous cord blood cells is feasible in about 70% of extremely preterm infants (<28 weeks gestation). No serious safety concerns were reported, supporting the potential for future therapies aimed at reducing neurodevelopmental complications in high risk newborns.
Trusted by families for 30 years and recognized by the following organizations and associations
ViaCord is proud to be a part of Revvity, a leading global healthcare company.
Disclaimer: Banking cord blood does not guarantee that treatment will work, and only a doctor can determine when it can be used. Cord tissue stem cells have not been used in treatment yet. Research is ongoing. The content shall not be used to make a diagnosis or to replace or overrule a health care provider’s judgement. Always consult with a qualified and licensed physician or other medical care provider.
